Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Enhance your knowledge of approved and investigational antibody–drug conjugates targeting HER2, HER3, TROP2, or B7-H3 in lung cancer, including the differences in ADC characteristics, the latest efficacy and safety data, and strategies for optimal patient selection, through an on-demand webcast with accompanying slides and a ClinicalThought commentary.

Share

Program Content

Activities

ADCs in EGFR-Mutated NSCLC
Antibody–Drug Conjugates in EGFR-Mutated NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2024

Expires: September 15, 2025

ADCs in HER2-Mutated NSCLC
ADCs in HER2-Mutated NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2024

Expires: September 15, 2025

TROP 2 ADCs and ADCs in SCLC
Expanding the Applicability Beyond HER2m and EGFRm: TROP-2–Targeted ADCs in NSCLC and ADCs in Patients with SCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2024

Expires: September 15, 2025

Activities

ADCs for Lung Cancer
Latest Developments and Insights on ADCs for Lung Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2024

Expires: November 04, 2025

Activities

Guidance on Targeted ADCs for Lung Cancer
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2024

Expires: May 31, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.